Active Ingredient History

  • Now
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis and COVID-19.   Wikipedia

  • SMILES: CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nc(cs4)c5cccnc5)c3)CC1
  • Mol. Mass: 498.66
  • ALogP: 5.26
  • ChEMBL Molecule:
More Chemistry
4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide | ab1010 | ab 1010 | ab-1010 | kinavet ca-1 | masatinib | masican | masitinib | masitinib mesilate | masitinib mesylate | masivet


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue